Andelyn Biosciences selected to manufacture AAV therapies under CIRM
May 28, 2024
Source: drugdu
93
Andelyn Biosciences, a patient-focused cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies using its suspension AAV Curator Platform under the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
The CIRM partnership with Andelyn aims to advance BGTC’s mission to develop platforms and standards to propel the development and delivery of customised or ‘bespoke’ gene therapies for millions of people affected with rare diseases. BGTC is focusing on development of cures for eight such diseases, with Andelyn selected to optimise and scale the AAV therapy processes for the treatment of Congenital Hereditary Endothelial Dystrophy – Type 1.
With scalable end-to-end development and manufacturing capabilities across its three Columbus, Ohio facilities, Andelyn aims to work towards the progression of life-altering gene therapies for rare and prevalent diseases.
https://andelynbio.com/news-and-media/andelyn-biosciences-selected-as-viral-vector-manufacturing-partner-for-the-cirm-amp-bgtc/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- AI+Gene Therapy | Dyno partners with Roche, with a prepayment of $50 million and a total value exceeding $1 billion November 1, 2024
- The 3rd Analysis and Testing Summit Forum and Academic Annual Conference of the Journal of Analysis and Testing in 2024 grandly opened in Guangzhou November 1, 2024
- Total investment is 500 million yuan! The first integrated intelligent factory project for synthetic biology CDMO full process in Jiangsu Province has been launched November 1, 2024
- Determination to break up November 1, 2024
- Million-RMB-worth CAR-T Drugs Miss Out on Health Insurance Negotiations for the Fourth Time November 1, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
